Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
CV Sciences, Inc. reports financial results and operating updates for a consumer wellness business focused on hemp extracts, CBD products and natural wellness ingredients. News commonly covers revenue trends, gross margin, operating expense reductions, adjusted EBITDA, cash flow objectives and balance-sheet actions such as secured note amendments and convertible debt features.
Company updates also include product launches across +PlusCBD, +PlusHLTH, Ignite and Empowr, including CBD gummies, pet products, cannabinoid-free supplements and plant-based nutrition formulas. Recurring coverage also addresses the evolving regulatory environment for hemp-derived CBD and the company’s efforts to broaden its wellness product portfolio.
CV Sciences (OTCQB:CVSI) launched Empowr on February 26, 2026, a dairy-free, plant-based protein and creatine powder designed for everyday wellness. Empowr delivers 20g protein, 5g creatine, and LactoSpore® probiotics per serving to support strength, mental energy, and digestive balance.
The product combines pea, hemp, and sunflower protein with creatine and Bacillus coagulans probiotics, expanding CV Sciences' wellness portfolio alongside its +PlusHLTH line.
CV Sciences (OTCQB:CVSI) said it is positioned to participate in a newly announced Medicare and Medicaid Pilot Program for CBD following an Executive Order directing HHS agencies to expand cannabidiol research and regulated access. The company highlighted its decade-long clinical research track record and its self-affirmed GRAS status for hemp extract products as bases for participation. The announcement notes CMS plans for a pilot to allow senior patients reimbursement for CBD, with a goal to begin on April 1, 2026.
CV Sciences (OTCQB:CVSI) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $3.3M, down from $3.9M in Q3 2024 and down from $3.6M in Q2 2025. Gross margin improved to 48.5% versus 46.0% a year earlier. Adjusted EBITDA was a loss of $118k versus a $75k loss in Q3 2024. Cash at quarter end was $0.4M. Units sold declined by 16% year-over-year. Management highlighted new product expansion, including the launch of Ignite, and cited restrictive federal hemp language with a one-year delayed effect.
The company will host a conference call and webcast today at 4:30pm EDT/1:30pm PDT.
CV Sciences (OTCQB: CVSI) will release its third quarter 2025 financial results after market close on Thursday, November 13, 2025.
The company will host a conference call with investors at 1:30 p.m. PT / 4:30 p.m. ET on the same day. A live webcast will be available on the investor relations site at https://ir.cvsciences.com/news-events and directly at the provided webcast link. The webcast will be archived for approximately 30 days.
Live call participants may dial (877) 407-0784 (U.S.) or (201) 689-8560 (international); callers are asked to dial 15 minutes early. A telephone replay will be available about two hours after the call until Thursday, November 20, 2025 via replay numbers and confirmation code 13756671.
CV Sciences (OTCQB:CVSI) has launched Ignite, a new men's performance formula combining clinically-supported botanicals with full spectrum CBD. The product targets men aged 35+ seeking natural support for vitality, recovery, and focus.
The formula features key botanicals including Tongkat Ali for testosterone and energy support, Panax Ginseng for stamina and focus, and Tribulus Terrestris for libido enhancement. This launch adds to CV Sciences' expanding product portfolio, which includes +PlusHLTH™, +PlusCBD™ Extra Support Sleep and Calm Gummies, Reserve gummies, and pet products.
CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts, reported its Q2 2025 financial results. Revenue reached $3.6 million, down 8% from Q2 2024's $4.0 million, primarily due to state regulatory pressures affecting sales volume.
The company achieved its highest gross margin in 23 quarters at 50.9%, up from 47.0% in Q2 2024. CV Sciences reported positive adjusted EBITDA of $0.1 million, its first positive EBITDA since Q2 2019, compared to a $6,000 loss in Q2 2024. Cash balance improved to $0.9 million from $0.5 million at 2024 year-end.
Notably, 39% of Q2 2025 revenue came from new products launched since January 2023, with 34 new products introduced during this period. The company continues to focus on organic growth through product development and M&A opportunities while working to improve profitability through in-sourcing production via its Elevated Softgels acquisition.
CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has scheduled its Q2 2025 earnings release for August 13, 2025 after market close.
The company will host a conference call with investors at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access the webcast through the company's IR website or dial in directly. A replay will be available until August 20, 2025.
CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts, commends Texas Governor Greg Abbott's decision to veto Senate Bill 3. The bill would have effectively banned the sale of consumable hemp products in Texas.
The vetoed legislation posed a significant threat to Texas's hemp industry, which provides employment to thousands and supplies wellness products statewide. Governor Abbott emphasized the need for a regulatory framework that ensures public safety, aligns with federal law, maintains proper enforcement funding, and can be implemented without delays.
CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has scheduled its Q1 2025 earnings release for May 14, 2025, after market close. The company will host a conference call with investors at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time) on the same day.
Investors can access the webcast through the company's Investor Relations website or dial in directly. U.S. participants can call (877) 407-0784, while international callers should use (201) 689-8560. A replay will be available until May 21, 2025, accessible by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) with confirmation code 13753631.